EUDA Health Holdings Limited (NASDAQ:EUDA) Sees Large Decline in Short Interest

EUDA Health Holdings Limited (NASDAQ:EUDA) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totaling 5,223 shares, a decline of 37.3% from the May 31st total of 8,334 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 4,093 shares, the short-interest ratio is currently 1.3 days.

Institutional Investors Weigh In On EUDA Health

A hedge fund recently bought a new stake in EUDA Health stock. Jane Street Group LLC bought a new stake in shares of EUDA Health Holdings Limited (NASDAQ:EUDA) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 25,675 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 0.07% of EUDA Health as of its most recent filing with the SEC. Hedge funds and other institutional investors own 4.35% of the company’s stock.

EUDA Health Trading Up 3.5%

NASDAQ:EUDA traded up $0.49 on Thursday, hitting $14.49. 1,213 shares of the stock were exchanged, compared to its average volume of 69,217. The stock has a fifty day moving average of $14.97 and a 200-day moving average of $20.96. The stock has a market cap of $43.34 million, a PE ratio of -6.04 and a beta of 0.68. EUDA Health has a fifty-two week low of $5.26 and a fifty-two week high of $86.00.

EUDA Health (NASDAQ:EUDA) last issued its earnings results on Tuesday, May 5th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.76. The firm had revenue of $1.92 million for the quarter, compared to analysts’ expectations of $3.90 million. As a group, analysts predict that EUDA Health will post 1.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EUDA has been the subject of several analyst reports. Weiss Ratings downgraded EUDA Health from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 8th. Greenridge Global lowered their price objective on EUDA Health from $120.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Finally, Zacks Research upgraded EUDA Health from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $55.00.

About EUDA Health

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.